Similarly, the PPARγ agonist rosiglitazone (RGZ) suppressed the expression of angiogenic factors in MM cells (HIF-1α and IGF-1) and inhibited proliferation and reduced viability of RPMI-8226 cells in a concentration- and time-dependent manner (84). This evidence concerns the gene IGF1 and Miyoshi myopathy.